Ewing’s Sarcoma: Standard and Experimental Treatment Options
Tóm tắt
Từ khóa
Tài liệu tham khảo
Herzog, C.E., Overview of sarcomas in the adolescent and young adult population. J Pediatr Hematol Oncol, 2005. 27(4): p. 215-8. doi: 10.1097/01.mph.0000161762.53175.e4 .
Ewing, J., Classics in oncology. Diffuse endothelioma of bone. James Ewing. Proceedings of the New York Pathological Society, 1921. CA Cancer J Clin, 1972. 22(2): p. 95-8. doi: 10.3322/canjclin.22.2.95 .
Angervall, L. and F.M. Enzinger, Extraskeletal neoplasm resembling Ewing’s sarcoma. Cancer, 1975. 36(1): p. 240-51. doi: 10.1002/1097-0142(197507)36:1<240::AID-CNCR2820360127>3.0.CO;2-H .
Askin, F.B., et al., Malignant small cell tumor of the thoracopulmonary region in childhood: a distinctive clinicopathologic entity of uncertain histogenesis. Cancer, 1979. 43(6): p. 2438-51. doi: 10.1002/1097-0142(197906)43:6<2438::AID-CNCR2820430640>3.0.CO;2-9 .
Jaffe, R., et al., The neuroectodermal tumor of bone. Am J Surg Pathol, 1984. 8(12): p. 885-98. doi: 10.1097/00000478-198412000-00001 .
de Alava, E. and W.L. Gerald, Molecular biology of the Ewing’s sarcoma/primitive neuroectodermal tumor family. J Clin Oncol, 2000. 18(1): p. 204-13.
Seddon, B.M. and J.S. Whelan, Emerging chemotherapeutic strategies and the role of treatment stratification in Ewing sarcoma. Paediatr Drugs, 2008. 10(2): p. 93-105. doi: 10.2165/00148581-200810020-00004 .
Kim, S.Y., M. Tsokos, and L.J. Helman, Dilemmas associated with congenital ewing sarcoma family tumors. J Pediatr Hematol Oncol, 2008. 30(1): p. 4-7. doi: 10.1097/MPH.0b013e31815cf71f .
Folpe, A.L., et al., Morphologic and immunophenotypic diversity in Ewing family tumors: a study of 66 genetically confirmed cases. Am J Surg Pathol, 2005. 29(8): p. 1025-33.
Lazar, A., et al., Molecular diagnosis of sarcomas: chromosomal translocations in sarcomas. Arch Pathol Lab Med, 2006. 130(8): p. 1199-207.
Khoury, J.D., Ewing sarcoma family of tumors: a model for the new era of integrated laboratory diagnostics. Expert Rev Mol Diagn, 2008. 8(1): p. 97-105. doi: 10.1586/14737159.8.1.97 .
Avigad, S., et al., The predictive potential of molecular detection in the nonmetastatic Ewing family of tumors. Cancer, 2004. 100(5): p. 1053-8. doi: 10.1002/cncr.20059 .
Zoubek, A., et al., Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewing tumor patients? J Clin Oncol, 1996. 14(4): p. 1245-51.
de Alava, E., et al., EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing’s sarcoma. J Clin Oncol, 1998. 16(4): p. 1248-55.
Lin, P.P., et al., Differential transactivation by alternative EWS-FLI1 fusion proteins correlates with clinical heterogeneity in Ewing’s sarcoma. Cancer Res, 1999. 59(7): p. 1428-32.
Ludwig, J.A., Ewing sarcoma: historical perspectives, current state-of-the-art, and opportunities for targeted therapy in the future. Curr Opin Oncol, 2008. 20(4): p. 412-8.
Falk, S. and M. Alpert, Five-year survival of patients with Ewing’s sarcoma. Surg Gynecol Obstet, 1967. 124(2): p. 319-24.
Sutow, W.W. and M.P. Sullivan, Cyclophosphamide therapy in children with Ewing’s sarcoma. Cancer Chemother Rep, 1962. 23: p. 55-60.
Pinkel, D., Cyclophosphamide in children with cancer. Cancer, 1962. 15: p. 42-9. doi: 10.1002/1097-0142(196201/02)15:1<42::AID-CNCR2820150107>3.0.CO;2-D .
Johnson, R. and S.R. Humphreys, Past failures and future possibilities in Ewing’s sarcoma. Experimental and preliminary clinical results. Cancer, 1969. 23(1): p. 161-6. doi: 10.1002/1097-0142(196901)23:1<161::AID-CNCR2820230121>3.0.CO;2-L .
Senyszyn, J.J., R.E. Johnson, and R.E. Curran, Treatment of metastatic Ewing’s sarcoma with actinomycin D (NSC-3053). Cancer Chemother Rep, 1970. 54(2): p. 103-7.
Hustu, H.O., D. Pinkel, and C.B. Pratt, Treatment of clinically localized Ewing’s sarcoma with radiotherapy and combination chemotherapy. Cancer, 1972. 30(6): p. 1522-7. doi: 10.1002/1097-0142(197212)30:6<1522::AID-CNCR2820300617>3.0.CO;2-J .
Oldham, R.K. and T.C. Pomeroy, Treatment of Ewing’s sarcoma with adriamycin (NSC-123127). Cancer Chemother Rep, 1972. 56(5): p. 635-9.
Rosen, G., et al., Proceedings: Disease-free survival in children with Ewing’s sarcoma treated with radiation therapy and adjuvant four-drug sequential chemotherapy. Cancer, 1974. 33(2): p. 384-93. doi: 10.1002/1097-0142(197402)33:2<384::AID-CNCR2820330213>3.0.CO;2-T .
Hayes, F.A., et al., Therapy for localized Ewing’s sarcoma of bone. J Clin Oncol, 1989. 7(2): p. 208-13.
Jurgens, H., et al., Multidisciplinary treatment of primary Ewing’s sarcoma of bone. A 6-year experience of a European Cooperative Trial. Cancer, 1988. 61(1): p. 23-32. doi: 10.1002/1097-0142(19880101)61:1<23::AID-CNCR2820610106>3.0.CO;2-M .
Razek, A., et al., Intergroup Ewing’s Sarcoma Study: local control related to radiation dose, volume, and site of primary lesion in Ewing’s sarcoma. Cancer, 1980. 46(3): p. 516-21. doi: 10.1002/1097-0142(19800801)46:3<516::AID-CNCR2820460316>3.0.CO;2-K .
Grier, H.E., et al., Addition of ifosfamide and etoposide to standard chemotherapy for Ewing’s sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med, 2003. 348(8): p. 694-701. doi: 10.1056/NEJMoa020890 .
Paulussen, M., et al., Ewing’s sarcoma of the bone: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol, 2008. 19 Suppl 2: p. ii97-8. doi: 10.1093/annonc/mdn103 .
Womer RB, West DC, Krailo MD, Dickman PS, Pawel B, for the Children’s Oncology Group AEWS0031 Committee: Randomized comparison of every-two-week v. every-three-week chemotherapy in Ewing sarcoma family tumors (ESFT). J Clin Oncol 2008, 26(May 20 suppl; abstr 10504)
Ferrari, S, et al.: Response to high-dose ifosfamide in patients with advanced/recurrent Ewing sarcoma. Pediatr Blood Cancer 2009
Laskar, S., et al., Post-operative radiotherapy for Ewing sarcoma: when, how and how much? Pediatr Blood Cancer, 2008. 51(5): p. 575-80. doi: 10.1002/pbc.21657 .
Indelicato, D.J., et al., Definitive radiotherapy for ewing tumors of extremities and pelvis: long-term disease control, limb function, and treatment toxicity. Int J Radiat Oncol Biol Phys, 2008. 72(3): p. 871-7. doi: 10.1016/j.ijrobp.2008.02.023 .
Indelicato, D.J., et al., Long-term clinical and functional outcomes after treatment for localized Ewing’s tumor of the lower extremity. Int J Radiat Oncol Biol Phys, 2008. 70(2): p. 501-9. doi: 10.1016/j.ijrobp.2007.06.032 .
Schuck, A., et al., Local therapy in localized Ewing tumors: results of 1058 patients treated in the CESS 81, CESS 86, and EICESS 92 trials. Int J Radiat Oncol Biol Phys, 2003. 55(1): p. 168-77. doi: 10.1016/S0360-3016(02)03797-5 .
Bacci, G., et al., Long-term outcome for patients with non-metastatic Ewing’s sarcoma treated with adjuvant and neoadjuvant chemotherapies. 402 patients treated at Rizzoli between 1972 and 1992. Eur J Cancer, 2004. 40(1): p. 73-83. doi: 10.1016/j.ejca.2003.08.022 .
Donaldson, S.S., et al., A multidisciplinary study investigating radiotherapy in Ewing’s sarcoma: end results of POG #8346. Pediatric Oncology Group. Int J Radiat Oncol Biol Phys, 1998. 42(1): p. 125-35. doi: 10.1016/S0360-3016(98)00191-6 .
Krasin, M.J., et al., Definitive irradiation in multidisciplinary management of localized Ewing sarcoma family of tumors in pediatric patients: outcome and prognostic factors. Int J Radiat Oncol Biol Phys, 2004. 60(3): p. 830-8. doi: 10.1016/j.ijrobp.2004.04.006 .
Donaldson, S.S., Ewing sarcoma: radiation dose and target volume. Pediatr Blood Cancer, 2004. 42(5): p. 471-6. doi: 10.1002/pbc.10472 .
Cotterill, S.J., et al., Prognostic factors in Ewing’s tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing’s Sarcoma Study Group. J Clin Oncol, 2000. 18(17): p. 3108-14.
Kolb, E.A., et al., Long-term event-free survival after intensive chemotherapy for Ewing’s family of tumors in children and young adults. J Clin Oncol, 2003. 21(18): p. 3423-30. doi: 10.1200/JCO.2003.10.033 .
Sinkovics, J.G., et al., Ewing sarcoma: its course and treatment in 50 adult patients. Oncology, 1980. 37(2): p. 114-9.
Siegel, R.D., L.M. Ryan, and K.H. Antman, Adults with Ewing’s sarcoma. An analysis of 16 patients at the Dana-Farber Cancer Institute. Am J Clin Oncol, 1988. 11(6): p. 614-7. doi: 10.1097/00000421-198812000-00003 .
Picci, P., et al., Chemotherapy-induced tumor necrosis as a prognostic factor in localized Ewing’s sarcoma of the extremities. J Clin Oncol, 1997. 15(4): p. 1553-9.
Verrill, M.W., et al., Ewing’s sarcoma and primitive neuroectodermal tumor in adults: are they different from Ewing’s sarcoma and primitive neuroectodermal tumor in children? J Clin Oncol, 1997. 15(7): p. 2611-21.
Fizazi, K., et al., Ewing’s family of tumors in adults: multivariate analysis of survival and long-term results of multimodality therapy in 182 patients. J Clin Oncol, 1998. 16(12): p. 3736-43.
Bacci, G., et al., Adjuvant and neoadjuvant chemotherapy for Ewing sarcoma family tumors in patients aged between 40 and 60: report of 35 cases and comparison of results with 586 younger patients treated with the same protocols in the same years. Cancer, 2007. 109(4): p. 780-6. doi: 10.1002/cncr.22456 .
Pieper, S., et al., Ewing’s tumors over the age of 40: a retrospective analysis of 47 patients treated according to the International Clinical Trials EICESS 92 and EURO-E.W.I.N.G. 99. Onkologie, 2008. 31(12): p. 657-63. doi: 10.1159/000165361 .
Paulussen M, Ahrens S, Juergens HF: Cure rates in Ewing tumor patients aged over 15 years are better in pediatric oncology units. Results of GPOH CESS/EICESS studies. ASCO 2003 Annual Meeting 2003
Dyke, J.P., et al., Osteogenic and Ewing sarcomas: estimation of necrotic fraction during induction chemotherapy with dynamic contrast-enhanced MR imaging. Radiology, 2003. 228(1): p. 271-8. doi: 10.1148/radiol.2281011651 .
Leavey, P.J. and A.B. Collier, Ewing sarcoma: prognostic criteria, outcomes and future treatment. Expert Rev Anticancer Ther, 2008. 8(4): p. 617-24. doi: 10.1586/14737140.8.4.617 .
Esiashvili, N., M. Goodman, and R.B. Marcus, Jr., Changes in incidence and survival of Ewing sarcoma patients over the past 3 decades: Surveillance Epidemiology and End Results data. J Pediatr Hematol Oncol, 2008. 30(6): p. 425-30. doi: 10.1097/MPH.0b013e31816e22f3 .
Leavey, P.J., et al., Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence following multi-modality therapy: A report from the Children’s Oncology Group. Pediatr Blood Cancer, 2008. 51(3): p. 334-8. doi: 10.1002/pbc.21618 .
Hustu, H.O., et al., Treatment of Ewing’s sarcoma with concurrent radiotherapy and chemotherapy. J Pediatr, 1968. 73(2): p. 249-51. doi: 10.1016/S0022-3476(68)80078-2 .
Saylors, R.L., 3rd, et al., Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. J Clin Oncol, 2001. 19(15): p. 3463-9.
Hunold, A., et al., Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors. Pediatr Blood Cancer, 2006. 47(6): p. 795-800. doi: 10.1002/pbc.20719 .
Anderson, P., et al., Novel bone cancer drugs: investigational agents and control paradigms for primary bone sarcomas (Ewing’s sarcoma and osteosarcoma). Expert Opin Investig Drugs, 2008. 17(11): p. 1703-15. doi: 10.1517/13543784.17.11.1703 .
Wagner, L.M., et al., Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors. Clin Cancer Res, 2004. 10(3): p. 840-8. doi: 10.1158/1078-0432.CCR-03-0175 .
Wagner, L.M., et al., Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma. Pediatr Blood Cancer, 2007. 48(2): p. 132-9. doi: 10.1002/pbc.20697 .
Kushner, B.H., et al., Irinotecan plus temozolomide for relapsed or refractory neuroblastoma. J Clin Oncol, 2006. 24(33): p. 5271-6. doi: 10.1200/JCO.2006.06.7272 .
Maki, R.G., et al., Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol, 2007. 25(19): p. 2755-63. doi: 10.1200/JCO.2006.10.4117 .
Ludwig, J.A. and J.N. Weinstein, Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer, 2005. 5(11): p. 845-56. doi: 10.1038/nrc1739 .
Schuetze, S.M., Chemotherapy in the management of osteosarcoma and Ewing’s sarcoma. J Natl Compr Canc Netw, 2007. 5(4): p. 449-55.
Ladenstein, R., et al., Impact of megatherapy in children with high-risk Ewing’s tumours in complete remission: a report from the EBMT Solid Tumour Registry. Bone Marrow Transplant, 1995. 15(5): p. 697-705.
Paulussen, M., et al., Primary metastatic (stage IV) Ewing tumor: survival analysis of 171 patients from the EICESS studies. European Intergroup Cooperative Ewing Sarcoma Studies. Ann Oncol, 1998. 9(3): p. 275-81. doi: 10.1023/A:1008208511815 .
Burdach, S., et al., Allogeneic and autologous stem-cell transplantation in advanced Ewing tumors. An update after long-term follow-up from two centers of the European Intergroup study EICESS. Stem-Cell Transplant Programs at Dusseldorf University Medical Center, Germany and St. Anna Kinderspital, Vienna, Austria. Ann Oncol, 2000. 11(11): p. 1451-62. doi: 10.1023/A:1026539908115 .
Meyers, P.A., et al., High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing’s sarcoma does not improve prognosis. J Clin Oncol, 2001. 19(11): p. 2812-20.
Burdach, S., et al., High-dose therapy for patients with primary multifocal and early relapsed Ewing’s tumors: results of two consecutive regimens assessing the role of total-body irradiation. J Clin Oncol, 2003. 21(16): p. 3072-8. doi: 10.1200/JCO.2003.12.039 .
Bhatia, S., et al., Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: A report from the Children’s Oncology Group. Blood, 2007. 109(1): p. 46-51. doi: 10.1182/blood-2006-01-023101 .
Hosono A, et al.: Segregated graft-versus-tumor effect between CNS and non-CNS lesions of Ewing’s sarcoma family of tumors. Bone Marrow Transplant 2008
Bolontrade, M.F., R.R. Zhou, and E.S. Kleinerman, Vasculogenesis Plays a Role in the Growth of Ewing’s Sarcoma in Vivo. Clin Cancer Res, 2002. 8(11): p. 3622-7.
Fuchs, B., C.Y. Inwards, and R. Janknecht, Vascular endothelial growth factor expression is up-regulated by EWS-ETS oncoproteins and Sp1 and may represent an independent predictor of survival in Ewing’s sarcoma. Clin Cancer Res, 2004. 10(4): p. 1344-53. doi: 10.1158/1078-0432.CCR-03-0038 .
Garcia-Carbonero, R., et al., Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol, 2004. 22(8): p. 1480-90. doi: 10.1200/JCO.2004.02.098 .
Sakai, R., et al., Additional antitumor ecteinascidins from a Caribbean tunicate: crystal structures and activities in vivo. Proc Natl Acad Sci U S A, 1992. 89(23): p. 11456-60. doi: 10.1073/pnas.89.23.11456 .
Martinez, N., et al., Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naive patients. Mol Cancer Ther, 2005. 4(5): p. 814-23. doi: 10.1158/1535-7163.MCT-04-0316 .
Kovar, H., et al., EWS/FLI-1 antagonists induce growth inhibition of Ewing tumor cells in vitro. Cell Growth Differ, 1996. 7(4): p. 429-37.
Tanaka, K., et al., EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing’s sarcoma and primitive neuroectodermal tumor cells. J Clin Invest, 1997. 99(2): p. 239-47. doi: 10.1172/JCI119152 .
Toretsky, J.A., et al., Inhibition of EWS-FLI-1 fusion protein with antisense oligodeoxynucleotides. J Neurooncol, 1997. 31(1-2): p. 9-16. doi: 10.1023/A:1005716926800 .
Lambert, G., et al., EWS fli-1 antisense nanocapsules inhibits ewing sarcoma-related tumor in mice. Biochem Biophys Res Commun, 2000. 279(2): p. 401-6. doi: 10.1006/bbrc.2000.3963 .
Stegmaier, K., et al., Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma. PLoS Med, 2007. 4(4): p. e122. doi: 10.1371/journal.pmed.0040122 .
DuBois, S.G., et al., Phase II study of intermediate-dose cytarabine in patients with relapsed or refractory Ewing sarcoma: a report from the Children’s Oncology Group. Pediatr Blood Cancer, 2009. 52(3): p. 324-7. doi: 10.1002/pbc.21822 .
Toretsky, J.A., et al., The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts. J Biol Chem, 1997. 272(49): p. 30822-7. doi: 10.1074/jbc.272.49.30822 .
Scotlandi, K., et al., Insulin-like growth factor I receptor-mediated circuit in Ewing’s sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target. Cancer Res, 1996. 56(20): p. 4570-4.
Prieur, A., et al., EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol Cell Biol, 2004. 24(16): p. 7275-83. doi: 10.1128/MCB.24.16.7275-7283.2004 .
Benini, S., et al., Contribution of MEK/MAPK and PI3-K signaling pathway to the malignant behavior of Ewing’s sarcoma cells: therapeutic prospects. Int J Cancer, 2004. 108(3): p. 358-66. doi: 10.1002/ijc.11576 .
Manara, M.C., et al., Preclinical in vivo study of new insulin-like growth factor-I receptor–specific inhibitor in Ewing’s sarcoma. Clin Cancer Res, 2007. 13(4): p. 1322-30. doi: 10.1158/1078-0432.CCR-06-1518 .
Hurtubise, A., M.L. Bernstein, and R.L. Momparler, Preclinical evaluation of the antineoplastic action of 5-aza-2’-deoxycytidine and different histone deacetylase inhibitors on human Ewing’s sarcoma cells. Cancer Cell Int, 2008. 8: p. 16. doi: 10.1186/1475-2867-8-16 .
Dalal S, Burchill SA: Preclinical evaluation of vascular-disrupting agents in Ewing’s sarcoma family of tumours. Eur J Cancer 2009
Zhou, Z., et al., Suppression of Ewing’s sarcoma tumor growth, tumor vessel formation, and vasculogenesis following anti vascular endothelial growth factor receptor-2 therapy. Clin Cancer Res, 2007. 13(16): p. 4867-73. doi: 10.1158/1078-0432.CCR-07-0133 .
Schaefer KL, et al.: Microarray analysis of Ewing’s sarcoma family of tumours reveals characteristic gene expression signatures associated with metastasis and resistance to chemotherapy. Eur J Cancer 2008
Uren, A., et al., Wnt/Frizzled signaling in Ewing sarcoma. Pediatr Blood Cancer, 2004. 43(3): p. 243-9. doi: 10.1002/pbc.20124 .